Ekene Enemchukwu, MD, MPH, FACS, URPS

“Given the rates in epidemiologic studies and surveys showing that up to 70% of women are symptomatic, we were surprised to find that only 9% [filled] a prescription,” says Ekene Enemchukwu, MD, MPH, FACS, URPS.

"What we found is that 9% of women with a GSM-related diagnosis filled a prescription for vaginal estrogen during the study period, and these women tended to be younger," says Ekene Enemchukwu, MD, MPH, FACS, URPS.

“To find a therapy that's all encompassing, that manages all of this in a long-term fashion, low-dose vaginal estrogen is the preferred treatment,” says Ekene Enemchukwu, MD, MPH, FACS, URPS.